31 results on '"Richardson, P. G."'
Search Results
2. Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
3. Ixazomib-induced cutaneous necrotizing vasculitis
4. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
5. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation
6. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
7. KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
8. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
9. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
10. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
11. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia
12. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
13. Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
14. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
15. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)
16. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
17. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors
18. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
19. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
20. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
21. The use of novel agents in the treatment of relapsed and refractory multiple myeloma
22. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
23. Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
24. The research mission in myeloma
25. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
26. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
27. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies
28. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway
29. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
30. Routine screening for psychosocial distress following hematopoietic stem cell transplantation
31. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.